Bio­gen ex­tends col­lab­o­ra­tion with Ei­sai

BioSpectrum (Asia) - - Company News -

Ei­sai Co., Ltd. and Bio­gen Inc. have ex­panded their ex­ist­ing agree­ment to jointly de­velop and com­mer­cial­ize in­ves­ti­ga­tional Alzheimer’s dis­ease treat­ments. Un­der the terms of the agree­ment Ei­sai has ex­er­cised its op­tion to co-de­velop and co­pro­mote ad­u­canumab, Bio­gen’s in­ves­ti­ga­tional anti-amy­loid beta (A beta) an­ti­body for pa­tients with Alzheimer’s dis­ease (AD).

The ex­panded agree­ment lever­ages each com­pany’s re­spec­tive ge­o­graphic strengths for com­mer­cial­iza­tion and ad­justs the re­spec­tive share of prof­its from po­ten­tial sales of ad­u­canumab. Bio­gen will re­ceive 55 per­cent of the po­ten­tial prof­its in the United States and 68.5 per­cent of the po­ten­tial prof­its in Europe.

Ei­sai will re­ceive 80 per cent of the po­ten­tial prof­its in Ja­pan and Asia (ex­clud­ing China and South Korea). The com­pa­nies will have a 50:50 co­pro­mo­tion split of po­ten­tial prof­its in the rest of the world. Fur­ther, Bio­gen will book sales in the United States, Europe, and rest of world mar­kets while Ei­sai will book sales in Ja­pan and Asia (ex­clud­ing China, South Korea). Bio­gen will con­tinue to lead the on­go­ing Phase 3 de­vel­op­ment of ad­u­canumab and will re­main solely re­spon­si­ble for all de­vel­op­ment costs for ad­u­canumab un­til April 2018.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.